CanAm Bioresearch Inc.

April 27, 2010 09:01 ET

CanAm Bioresearch Welcomes Dr. Marc Labelle to Team

WINNIPEG, MANITOBA--(Marketwire - April 27, 2010) - CanAm Bioresearch Inc., an innovative pharmaceutical CRO specializing in pre-clinical discovery and development, is pleased to announce an affiliation agreement with Dr. Marc Labelle.

Dr. Labelle has over 25 years of successful drug discovery and scientific leadership in a wide array of therapeutic areas. Dr. Labelle specializes in drug discovery sciences, with a strong expertise in modification of molecular structure to impart drug properties.

The addition of Dr. Labelle expands CanAm's capabilities in drug discovery and development services and enhances its client service offerings.

"Adding a widely recognized executive with the unique experience of leading the discovery of currently marketed pharmaceutical products complements the pre-clinical medicinal chemistry, pharmacology, bioanalytical and strategic consulting services already offered by CanAm Bioresearch to our clients", stated Mr. Marcus Enns, President of CanAm Bioresearch.

Dr. Labelle has served as Vice-President of Chemistry at both Lundbeck Research USA, and Imclone Systems, and as Director of Medicinal Chemistry at Tularik (now Amgen) and Merck Frosst Canada Ltd. At Merck Frosst, he led medicinal chemistry teams involved in the discovery of Singulair® and CORDAPTIVE™.

About Dr. Marc Labelle

Dr. Marc Labelle is an innovative and accomplished senior drug discovery scientist with a wide variety of experience both with international pharmaceutical companies and with global CROs. Dr. Labelle has extensive contacts with key opinion leaders and has research experience in a number of therapeutic areas including cardiovascular and metabolic disorders, oncology, gastroenterology and respirology. Dr. Labelle received his Ph.D in chemistry from the University of Montreal and was a post-doctoral fellow at Columbia University.

About CanAm Bioresearch Inc.

CanAm Bioresearch was established in 2000 as a pharmaceutical contract research organization specializing in pre-clinical discovery and development. CanAm provides custom chemical synthesis, bioanalytical, and pharmacology services. In combination with the pharmacology division, the talented team of medicinal chemists can assist clients to validate early drug candidates and further optimize lead drug candidates. CanAm offers competitive, cost-effective pricing and hands-on team work with both academic and industrial clients to achieve their research goals.

Contact Information